Interim report
Page 1
07th November, 2025 The Dy. General Manager (Listing Dept.) The Manager – Listing Dept ., BSE Limited, National Stock Exchange of India Ltd., Corporate Relationship Dept., Exchange Plaza, 5th Floor, 1st Floor, New Trading Ring, Plot No. C/1, G. Block, P. J. Towers, Dalal Street, Fort, Bandra - Kurla Complex, Bandra (E), Mumbai - 400 001 Mumbai – 400 051 ( BSE Scrip Code: 500420) (NSE Scrip Code: TORNTPHARM) Dear Sir, Sub.: Submission / Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) We would like to inform that the Board has at its meeting held today approved, inter alia, the Audited Standalone Financial Results along with audit report thereon and Unaudited Consolidated Financial Results along with limited review report of the Company for the quarter and half year ended 30th September, 2025. The said financial results are enclosed herewith. In terms of Regulation 47 of the Listing Regulations, the Company will publish an extract of Unaudited Consolidated Financial Results for the quarter and half year ended on 30 th September, 2025. Both Standalone and Consolidated Financial Results will be available at Company's website www.torrentpharma.com A Press Release on Financial Results which is being submitte d to the media is also enclosed herewith. The Board meeting commenced at 02:10 pm and concluded at 05:30 pm. The above is for your information and record. Thanking you, Yours Sincerely, For TORRENT PHARMACEUTICALS LIMITED CHINTAN M. TRIVEDI COMPANY SECRETARY Encl: A/a ___________________________________________________________________________________ TORRENT PHARMACEUTICALS LIMITED CIN: L24230GJ1972PLC002126 Reg.Office : Torrent House, Off Ashram Road, Ahmedabad- 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100, www.torrentpharma.com, Email : InvestorServices@TorrentPharma.com E3;orrent PHRRmR
Page 2
BS R & Co. LLP Chartered Accountants 14th Floor, Central B Wing and North C Wing Nesco IT Park 4, Nesco Center Western Express Highway Goregaon (East), Mumbai - 400 063, India Te~phone: +91(22)62571000 Fax:+91(22)62571010 lndeoendent Auditor's Reoort To the Board of Directors of Torrent Pharmaceuticals Limited Report on the audit of the Standalone Financial Results Opinion We have audited the accompanying standalone quarterly financial results of Torrent Pharmaceuticals Limited ("the Company") for the quarter ended 30 September 2025 and the year-to-date results for the period from 1 April 2025 to 30 September 2025, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021. In our opinion and to the best of our information and according to the explanations given to us, these standalone financial results: a. are presented in accordance with the requirements of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 in this regard; and b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive loss and other financial information for the quarter ended 30 September 2025 as well as for the year to date results for the period from 1 April 2025 to 30 September 2025. Basis for Opinion We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our opinion. Management's and Board of Directors' Responsibilities for the Standalone Financial Results These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Management and the Board of Directors are responsible for the preparation of these standalone financial results that give a true and fair view of the net profiU loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021 /613 dated 10 August 2021. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets ~ Registered Office: BS R & Co, (a partnership fiml vlith Registration No. BA61223) converted Into BS R & Co. LLP (a Limited Uabilily Partnership wilh LLP Reglstralion No. AAB..8181) with effect from October 14, 2013 14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nasca Center, Western Express Highway, Goregaon (Easl), Mumbai• 400063 Page 1 of 3
Page 3
B S R & Co. LLP . Independent Aud itor's Report (Continued) Torrent Pharmaceuticals Limited of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error. In preparing the standalone financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors is also responsible for overseeing ·the Company's financial reporting process. Auditor's Responsibilities for the Audit of the Standalone Financial Results Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also: Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control. - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone financial results made by the Management and Board of Directors. - Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern. - Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the standalone financial results represent the underlying transactions and events in a manner that achieves fair presentation. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. r ~&Co,( ~ Q:) <o + l+- 'a ) .'!! ~~--<# <!'red Acco~' Page 2 of 3
Page 4
BS R & Co. LLP Independent Auditor's Report (Continued) Torrent Pharmaceuticals Limited We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. Ahmedabad 07 November 2025 For B S R & Co. LLP Chartered Accountants Firm's Registration No.:101248W/W-100022 Sadashiv Shetty Partner Membership No.: 048648 UDIN :25048648 BMNY JS4686 Page 3 of 3
Page 5
E3-torrent- PHRRmR TORRENT PHARMACEUTICALS LIMITED Registered Office: Torrent House, Off Ashram Road, Ahmedabad - 380 009, Ph.: +91 79 26599000 Fax: + 91 79 26582100 CIN: L24230GJ1972PLC002126; Website:www .torrentpharma.com; Email: lnvestorservices@torrentpharm a.com Statement of Standalone Audited Financial Results for the Quarter and Half Year ended September 30, 202S Particulars Quarter ended Half Year ended 30-Sep-2025 30-Jun-2025 30-Sep-2024 30-Sep-2025 30-Sep-2024 1 Revenue from operations (a) Revenue from contracts with custom ers 2707 2567 2376 5274 4770 (b) Other operating income 55 49 58 104 102 Total revenue from operations 2762 2616 2434 5378 4872 2 Other incom e (Refer note 9) (27) (5) (7) (32) 14 3 Total Income (1 + 2} 2735 2611 2427 5346 4886 4 Expenses (a) Cost of materials consumed 382 394 337 776 747 (b) Purchases of stock-in-trade 186 173 175 359 316 (c) Changes in inventories of finished goods, work-in -progress 53 17 23 70 55 and stock-in-trade (d) Employee benefits expense 460 453 407 913 813 (e) Finance costs 37 45 54 82 118 (f) Depreciation and amortisation expense 189 187 190 376 379 (g) Other expenses 609 600 571 1209 1121 Total expenses 1916 1869 1757 3785 3549 5 Profit before exceptional items and tax (3 • 4) 819 742 670 1561 1337 6 Exceptional items (Refer note 6) 13 - - 13 - 7 Profit before tax (5 • 6) 806 742 670 1548 1337 8 Tax expense (Refer note 7) (a) Current tax 220 198 139 418 256 (b) Deferred tax (11) (7) 71 (18) 152 Total tax expense 209 191 210 400 408 9 Net profit for the period (7 • 8) 597 551 460 1148 929 10 Other comprehensive income (A) (i) Items that will not be reclassified subsequently to (2) (9) (7) (11) (12) profit or loss (ii) Income tax relating to items that will not be 1 2 2 3 4 reclassified subsequently to profit or loss (B) (i) Items that will be reclassified subsequently to profit or (72) (27) (37) (99) (32) loss (ii) Income tax relating to items that will be reclassified 18 7 13 25 11 subsequently to profit or loss Total other comprehensive Income (55) (27) (29) (82) (29) 11 Total comprehensive income (9 + 10) 542 524 431 1066 900 12 Paid-up equity share capital (Face value of Rs. 5 each) 169.23 169.23 169.23 169.23 169.23 13 Other equity excluding revaluation reserves 14 Earnings per share (Face value of Rs. 5 each) (not annualised) : Basic (in Rs.) 17.64 16.28 13.60 33.92 27.46 Diluted (in Rs.) 17.64 16.28 13.60 33.92 27.46 See accompanying notes to the standalone financial results (Rs. In crores) Year ended 31-Mar-2025 9485 197 9682 32 9714 1518 732 (9) 1636 213 760 2230 7080 2634 24 2610 541 181 722 1888 (33) 8 (23) 7 (41) 1847 169.23 7423 55.79 55.79
Page 6
O!lli-torre nf- Q;;;, PHARmA Notes: 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on November 7, 2025. The statutory auditors have carried out an audit of the above said results. There is no qualification in the auditor's report on this statement offinancial results. 2 The Company operates in a single segment i.e. Generic Formulation Business. 3 Standalone Balance Sheet Particulars A ASSETS 1 Non-current assets Property, plant and equipment Capital work-in-progress Right-of-use assets Goodwill Other intangible assets Intangible assets under development Financial assets Investments Loans Other financial assets Other tax assets (net) Other non-current assets Total non-current assets 2 Current assets Inventories Financial assets Investments Trade receivables Cash and cash equivalents Bank balances other than cash and cash equivalents Loans Other financial assets Other current assets Total current assets 3 Non-current assets held for sale TOTAL ASSETS (1+2+3) ~<tP.J.Cfu,-./. ~~ c:, Q. f' ... E3~ "'I z -- ,-..u • ... rJ., ~ O'o "'>..,. ./. * 0. (Rs. in crores) Audited As at As at 30-Sep-2025 31-Mar-2025 2910 2975 485 365 191 157 324 324 3845 4099 49 36 441 411 4 3 12 17 457 431 66 64 26 42 8353 8493 1493 1561 89 112 2634 2171 64 105 84 5 5 4 186 125 3062 2522 396 266 4951 4349 21 - 13325 12842
Page 7
E3-torrent- F'HAR m R (Rs. in crores) Audited Particulars Asat As at 30-Sep-2025 31-Mar-2025 B EQUITY AND LIABILITIES 1 Equity Equity share capita I 169 169 Other equity 8286 7423 Total equity 8455 7592 2 Non-current liabilities Financial liabilities Borrowings 867 1021 Lease liabilities 102 69 Other financial liabilities 57 14 1026 1104 Provisions 366 338 Deferred tax liabilities (net) 785 828 Other non-current liabilities* 0 0 Total non-current liabilities 2177 2270 3 Current liabilities Financial liabilities Borrowings 1127 1526 Lease liabilities 19 14 Trade payables Total outstanding dues of micro enterprises and small 63 23 enterprises Total outstanding dues of creditors other than micro 700 744 enterprises and small enterprises Other financial liabilities 345 291 2254 2598 Other current liabilities 78 102 Provisions 237 207 Current tax liabilities (net) 124 73 Total current liabilities 2693 2980 TOTAL EQUITY AND LIABILITIES (1+2+3) 13325 12842 * Represents value less than Rs. 0.50 crore.
Page 8
E3--torren f- PHRR m R 4 Standalone Statement of Cash Flows (Rs. in crores) Audited Particulars Half Year ended Half Year ended 30-Sep-2025 30-Sep-2024 A CASH FLOWS FROM OPERATING ACTIVITIES PROFIT BEFORE TAX 1548 1337 Adjustments for : Depreciation and amortisation expense 376 379 Allowance for expected credit loss (net)* 0 2 Unrealised foreign exchange loss (net) 40 3 Loss on disposal of property, plant & equipment and other 1 5 intangible assets (net) Gain on sale of current investments (net) (9) (8) Finance costs 82 118 Interest income* (2) 0 2036 1836 Movement in working capital: Trade receivables (428) (375) Loans and other assets (126) (68) Inventories 68 137 Trade payables (7) (137) Liabilities and provisions (91) 39 CASH GENERATED FROM OPERATIONS 1452 1432 Income taxes paid (net of refunds) (365) (214) NET CASH FROM OPERATING ACTIVITIES 1087 1218 B CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property, plant and equipment and other intangible (171) (126) assets (including payment towards capital work-in-progress, intangi ble assets under development and capital advances) Proceeds from disposal of property, plant & equipment and other 1 0 intangible assets (Including advance received against non current asset held for sale)* Payment for additional investment in subsidiaries (including share (31) (76) application money pending allotment) Payment for non-current investments - (10) Proceeds from redemption of mutual funds (net) 32 64 (Investment in)/ Maturity of fixed deposits (net)* (68) 0 Interest received* 2 0 NET CASH USED IN INVESTING ACTIVITIES (235) (148) * Represents value less than Rs. 0.50 crore.
Page 9
E3--torrent- PHARmR (Rs. in crores) Audited Particulars Half Year ended Half Year ended 30-Sep-2025. 30-Sep-2024 C CASH FLOWS FROM FINANCING ACTIVITIES Repayment of long-ter m borrowings (306) (189) Repayment of short term borrowings (net) {248) {603) Repayment of lease liabilities {11) (2) Dividend paid (203) {203) Interest and other borrowing cost paid (125) (87) NET CASH USED IN FINANCING ACTIVITIES (893) (1084) NET (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS (41) (14) (A+B+C) CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD 105 105 CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD 64 91 5 On June 29, 2025, the Company has entered into definitive agreement with Tau Investment Holdings Pte. Ltd to acquire controlling stake in J.B. Chemicals & Pharmaceuticals Limited (JB Pharma) subject to receipt of applicable statutory and regulatory approvals. The proposed transaction will be executed in two phases: a) Acquisition of 46.39% equity stake (on fully diluted basis) at a cash consideration of Rs. 1,600 per equity share aggregating to a total consideration of approximately Rs. 11,917 crores and conduct mandatory open offer at a price of Rs. 1,639 .18 per equity share in accordance with Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended ("SAST Regulations"). In addition, the Company has entered into definitive agreement with certain employees. of JB Pharma, pursuant to which 2.41% equity stake (on fully diluted basis) may be acquired at a price of Rs. 1,600 per equity share. b) Merger of JB Pharma with the Company as a going concern through a scheme of arrangement . Upon receipt of requisite approvals, the Company will issue 51 fully paid-up equity shares of the Company having face value of Rs. 5 each for every 100 fully paid-up equity shares of Rs. 1 each held in JB Pharma. The aforesaid transaction has no impact on the results for the quarter and half year ended September 30, 2025. The Company has received approval from Competition Commission of South Africa and Competition Commission of India (CCI) on September 22, 2025 and October 21, 2025 respectively. The CCI approval is subject to the parties complying with voluntary modifications to be outlined in CCl's final order. Further the Company has received SEBI Observation on Draft Letter of Offer on October 30, 2025. 6 (i) Exceptional items for the quarter and half year ended September 30, 2025, pertain to regulatory and statutory fees related to the proposed transaction as detailed in Note 5 above. (ii) Exceptional item for the year ended March 31, 2025 relates to a demand raised by the National Pharmaceutical Pricing Authority (NPPA) in 2017 concerning alleged overcharging, which was under judicial consideration before the Hon'ble Gujarat High Court. During the previous year, the Company submitted detailed representations, which were favourably considered by the NPPA. As a result, the Company's legal exposure was substantially reduced. Following the issuance of a revised demand by the NPPA, the Company opted to settle the litigation and bring the matter to a definitive close. 7 In the previous year, the Company assessed that it would transition to the new tax regime under Section 115BAA starting FY 2025- 26. Consequently, deferred tax balances expected to reverse in or after FY 2025- 26 were remeasured, resulting s. 151 crores for the year ended March 31, 2025. ,::::=~
Page 10
~ -torrent- ~ PHRRmR 8 The listed non-convertible debentures of the company aggregating Rs. 143 crores as at September 30, 2025 (previous year: Rs. 285 crores) are secured by way of first pari passu charge through mortgage on certain specified immovable assets, tangible movable assets and hypothecation of identified trademarks of the Company and the security cover thereof exceeds 100% of the principal amount and interest accrued of the said debentures . 9 Other income mainly includes interest income, dividend income, net gain on sale of investments, net foreign exchange gain/(loss) and net gain/(loss) on disposal of property, plant & equipment and other intangible assets. 10 Refer Annexure I for disclosure required pursuant to Regulation 52(4) and 54(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). Place : Ahmedabad, Gujarat Date: November 7, 2025 For TORRENT PHARMACEUTICALS LIMITED KHTA Managing Director DIN : 08174906
Page 11
E3-to rre nr P H AR m R ANNEXURE I : (Rs, in crores except as stated otherwise) Additional Disclosure as per regulation 52(4) and 54(3) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, Particulars Regulation No. Paid up debt capital Net worth 52(4)(f) Debenture redemption reserve 52(4)(e) Debt equity ratio (in times) 52(4)(a) Debt service coverage ratio (in times) 52(4)(b) Interest service coverage ratio (in times) 52(4)(c) Current ratio (in times) 52(4)(i) Long term debt to worki ng capital (in tim es)· 52(4)(j) Bad debts to Account receivables ratio (in times) 52(4)(k) Current liability ratio (in times) 52(4)(1) Total debts to tota l assets (in times) 52(4)(m) Debtors turnover (in times) (Annualised) 52(4)(n) Inventory turnover (in times) (Annualised) 52(4)(0) Operating margin (in %) 52(4)(p) Net profit margin (in %) 52(4)(q) Security cover ratio (in time s) 54(3) Ratios have been computed as follows :- (a) Debt equity ratio : Total debt/ Net worth Total debt: Non-current borrow ings+ current borrow ings Net worth: Equity share capital+ Other equity 2015 Quarter ended 30-Sep-2025 30-Jun-2025 643 643 8455 8117 36 36 0.24 0.27 3.19 5.55 22.30 17.21 1.85 1.71 0.48 0.60 0.00 0.00 0.55 0.56 0.15 0.17 4.33 4.52 7.15 6.63 37.8% 37.2% 21.6% 21.1% 17.01 9.41 Half Vear ended Vear ended 30-Sep-2024 30-Sep-2025 30-Sep-2024 31-Mar-2025 786 643 786 643 7526 8455 7526 7592 71 36 71 36 0.34 0.24 0.34 0.34 5.42 4.01 5.12 4.08 14.51 19.52 13.44 14.43 1.68 1.85 1.68 1.46 0.91 0.48 0.91 0.82 0.00 0.00 0.00 0.00 0.48 0.55 0.48 0.57 0.20 0.15 0.20 0.20 5.05 4.39 5.43 5.07 6.52 6.91 6.37 6.07 37.5% 37.5% 37.6% 37.2% 18.9% 21.3% 19.1% 19.5% 3.77 17.01 3.77 6.04 (b) Debt service coverage ratio : (Profit after tax+ Deferred tax+ Depreciation and amorti sation+ Interest on debt and lease + Exceptional items) / (Interest on debt and lease + Principal repayments of long term debt including lease payment) (c) Interest service coverage ratio: (Profit after tax+ Deferred tax + Depreciation and amortisation + Interest on debt and lease+ Exceptional items)/ Interest • on debt and lease (d) Current Ratio: Total current assets /Tota l current liabilit ies (e) Long term debt to worki ng capital : Non-current borrowi ngs (incl. current maturit ies of long-term borrowings)/ Net working capital Net Working capital : Total current assets• Current liabilities Current liabilitie s: Total current liabilities• current maturitie s of long-term borrowi ngs (fl Bad debts to Account receivables ratio: Allowances for expected credit loss/ Gross trade receivables (g) Current liability ratio : Total current liabilities/ Total liabilities (h) Total debts to tota l assets : Total borrowing/ Total assets Total borrowing : Non-current borrowings + current borrow ings (i) Debtors turnover : Net sales/ Average trade receivables (j) Inventory turnover : Net sales/ Average Inventories (k) Operating margin% : Revenue from operations • (cost of goods sold + employee benefits+ oth er expenses)+ (other income · inter est income - dividend income)/ Revenue from operation s (I) Net profi t margin % : Profit after tax / Revenue from operations (m) Security cover ratio : Total assets available for secured debt securities (secured by either pari-passu or exclusive charge on assets including assets given on first pari-passu basis to term loan lenders) / Total borrow ing through issue of secured Debt securiti es and oth er borrowing s (secured by first pari-passu charge on aforementioned assets) including interest accrued.
Page 12
BS R & Co. LLP Chartered Accountants 14th Floor, Central B Wing and North C Wing Nesco IT Park 4, Nesco Center Western Express Highway Goregaon (East), Mumbai - 400 063, India Telephone: +91 (22) 6257 1000 Fax: +91 (22) 6257 1010 Limited Review Report on unaudited consolidated financial results of Torrent Pharmaceuticals Limited for the quarter ended 30 September 2025 and year to date results for the period from 1 April 2025 to 30 September 2025 pursuant to Regulation 33 and Regulation 52(4) read with Regulation 63 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended To the Board of Directors of Torrent Pharmaceuticals Limited 1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Torrent Pharmaceuticals Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 September 2025 and year to date results for the period from 1 April 2025 to 30 September 2025 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended. 2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021 /613 dated 1 O August 2021, as amended. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable. 4. The Statement includes the results of the entities mentioned in Annexure I to the Statement. BS R & Co. (a partnorship fim1 with Registration No. 8A61223) converted into BS R & Co, LLP (a Limited Liability Partnership wiU1 LLP Registration No. MB..0161) with efrcct from October 14, 2013 Registered Office: 141h Floor, Central B Wing and North C Wing, Nesco IT Part< 4. Nesco Cenler. Western Express Highway, Goregaon (East), Mumbai - 400063 Page 1 of 4
Page 13
BS R & Co. LLP Limited Review Report (Continued) Torrent Pharmaceut icals Limited 5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021,as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. Ahmed a bad 07 November 2025 For B S R & Co. LLP Chartered Accountants Firm's Registration No.: 101248W/W-100022 Sadashiv Shetty Partner Membership No.: 048648 UDIN:25048648BMNY JV7301 Page 2 of 4
Page 14
BS R & Co. LLP Limited Review Report (Continued) Torrent Pharmaceuticals Limited Annexure I List of entities included in unaudited consolidated financial results. Sr. No Name of component Relationship 1 Torrent Pharmaceuticals Limited Parent 2 Zao Torrent Pharma Wholly Owned Subsidiary 3 Torrent Do Brasil Ltda Wholly Owned Subsidiary 4 Torrent Pharma Inc. Wholly Owned Subsidiary 5 Torrent Pharma Gmbh Wholly Owned Subsidiary 6 Heumann Pharma Gmbh & Co. Generica KG Wholly Owned Step down Subsidiary 7 Heunet Pharma Gmbh Wholly Owned Step down Subsidiary 8 Torrent Australasia Pty Ltd Wholly Owned Subsidiary 9 Torrent Pharma (Thailand) Co., Ltd. Wholly Owned Subsidiary 10 Torrent Pharma (UK) Ltd Wholly Owned Subsidiary 11 Laboratories Torrent (Malaysia) SDN.BHD. Wholly Owned Subsidiary 12 Torrent Pharma Philippines Inc Wholly Owned Subsidiary 13 Laboratories Torrent, S.A. de C.V Wholly Owned Subsidiary 14 TPL (Malta) Limited Wholly Owned Subsidiary 15 Torrent Pharma (Malta) Limited Wholly Owned Step down Subsidiary 16 Curatio Inc., Philippines Wholly Owned Subsidiary 17 Torrent International Lanka (Pvt) Ltd (Formely Wholly Owned Subsidiary known as Curatio International Lanka (Pvt) ~ Ltd), Sri Lanka ~ ?---o. / '~f '\<'.~ ~ l • , .. Page 3 of 4 'J. I°$ ~~~'ti 0red Acco~~ -
Page 15
BS R & Co. LLP 18 19 Limited Review Report (Continued) Torrent Pharmaceuticals Limited Farmaceutica Torrent Colombia SAS Wholly Owned Subsidiary Torrent Pharmaceuticals Chile SpA ("Torrent Wholly Owned Subsidiary Pharma Chile") Page 4 of 4
Page 16
ffl--torr ent- ~ P HRR ffi A TORRENT PHARMACEUTICALS LIMITED Registered Office: Torrent House, Off Ashram Road, Ahmedabad - 380 009, Ph.:+ 917926599000 Fax:+ 91 79 26582100 CIN: L24230GJ1972PLC002126; Website:www.torrentpharma.com; Email: investorservices@torrentpharma.com Statement of Consolidated Financial Results for the Quarter and Half Year ended September 30, 2025 Quarter ended Half Year ended Particulars 30-Sep-2025 30-Jun-2025 30-Sep-2024 30-Sep-2025 30-Sep-2024 1 Revenue from operations (a) Revenue from contracts with customers (b) Other operating income Total revenue from operations 2 Other income (Refer Note 9) 3 Total income (1+2) 4 Expenses (a) Cost of materials consumed (b) Purchases of stock-in-trade (c) Changes in inventories of finished goods, work-in- progress and stock-in-trade (d) Employee benefits expense (e) Finance costs (f) Depreciation and amortisation expense (g) Other expenses Total expenses 5 Profit before exceptional items and tax (3 - 4) 6 Exceptional items (Refer Note 7) 7 Profit before tax (5 - 6) 8 Tax expense (Refer Note 8) (a) Current tax (b) Deferred tax Total tax expense 9 Net profit for the period (7 - 8) Attributable to : (a) Owners of the company (b) Non-controlling interests 10 Other comprehensive income (A) (i) Items that will not be reclassified subsequently to profit or loss (ii) Income tax relating to items that will not be reclassified subsequently to profit or loss (B) (i) Items that will be reclassified subsequently to profit or loss (ii) Income tax relating to items that will be reclassified subsequently to profit or loss Total other comprehensive income Attributable to : (a) Owners of the company (b) Non-controlling interests 11 Total comprehensive Income (9 + 10) Attributable to : (a) Owners of the company (b) Non-controlling interests 12 Paid-up equity share capital (Face value of Rs. 5 each) 13 Other equity excluding revaluation reserves 14 Earnings per share (Face value of Rs. 5 each) (not annualised): Basic (in Rs.) Diluted (in Rs.) See accompanying notes to the consolidated financial results Unaudited 3246 56 3302 (27) 327S 382 382 36 627 48 204 792 2471 804 13 791 233 (33) 200 591 591 (3) 1 (92) 18 (76) {76) 515 515 169.23 17.45 17.45 Unaudited 3128 50 3178 (37) 3141 396 338 40 605 56 201 767 2403 738 738 201 (11) 190 548 548 (9) 2 (2) 7 (2) (2) 546 546 169.23 16.19 16.19 Unaudited 2831 58 2889 (16) 2873 337 382 (41) 543 64 198 729 2212 661 661 156 52 208 453 453 (7) 2 (33) 13 (25) (25) 428 428 169.23 13.37 13.37 Unaudited 6374 106 6480 (64) 6416 778 720 76 1232 104 405 1559 4874 1542 13 1529 434 (44) 390 1139 1139 (12) 3 (94) 25 (78) (78) 1061 1061 169.23 33.64 33.64 Unaudited 5646 102 5748 8 5756 748 695 (71) 1093 139 395 1440 4439 1317 1317 282 125 407 910 910 (12) 4 (62) 11 (59) (59) 851 851 169.23 26.88 26.88 (Rs. in crores) Year ended 31-Mar-2025 Audited 11317 199 11516 23 11539 1520 1531 (275) 2203 252 795 2816 8842 2697 24 2673 619 143 762 1911 1911 (28) 6 (78) 7 (93) (93) 1818 1818 169.23 7422 56.47 56.47
Page 17
E3 -torrent- PHAR m A Notes: 1 The above results were reviewed by t he Audit Committee and approved by the Board of Directors of the Parent Company, in the ir respective meet ings held on November 7, 2025. The statutory auditors have carried out review of the above said results. There is no qualification in t he auditor 's repor t on t his statement of financia l results. 2 The consolidat ed fina ncial results include the financial results of Parent Company and its eighteen who lly owned subsidiaries. 3 The Group operates in a single segment i.e. Generic Formulat ion Business. 4 Consolidated Balance Sheet Particulars A ASSETS 1 Non-current assets Property, plant and equipment Capital work-in-progress Right-of-use assets Goodwi ll Other inta ngible assets Intangible assets under development Financial assets Investme nts Loans Other fin ancial assets Ot her tax assets (net) Deferred tax assets (net) Other non-current assets Total non-curre nt assets 2 Current assets Inventories Financial assets Investme nts Trade receivables Cash and cash equiva lents Bank balances other t han cash and cash equivalents Loans Other financ ial assets Other current assets Tota l current assets ,~r,.CEu ,- \'- .fc- :i:"' -? 3 Non-current assets held for sale Q. ~ 1 ~· ~~ 1'" 1 z pt1pftfflllt ,,_, TOTAL ASSETS (1+2+3) ' ~ • ~.:c, d--4-o, .... "»~ .. (Rs. in crores) Unaudited Audited As at As at 30-Sep-2025 31-Mar-2025 3165 3209 488 367 293 246 340 339 3911 4152 132 111 44 44 4 3 27 33 75 80 240 226 653 595 26 42 9323 9367 2467 2541 89 112 2185 1867 621 573 84 6 5 5 239 183 3223 2746 481 336 6171 5623 21 - 15515 14990
Page 18
E3 -to rrent- PHRR m R (Rs. in crores) Unaudited Audited Particulars As at As at 30-Sep-2025 31-Mar-2025 B EQUITY AND LIABILITIES 1 Equity Equity share capital 169 169 Other equity 8280 7422 Tota l equ ity 8449 7591 2 Non-current liabilities Financial liabilities Borrowings 1045 1192 Lease Liabilities 198 146 Other financia l liabi lities 57 14 1300 1352 Provisions 541 501 Deferred tax liabi lities (net) 785 829 Other non-current liabilities* 5 0 Tota l non-current liabilities 2631 2682 3 Current liabilities Financial liabilities Borrowings 1545 1834 Lease Liabilities 34 30 Trade payables Tota l outstanding dues of micro enterprises and small enterprises 63 23 Total outstanding dues of creditors other than micro enterprises 1612 1797 and small enterprises Other financial liabilities 465 393 3719 4077 Other current liabilities 126 136 Provisions 460 408 Current Tax Liabilities (net) 130 96 Total current liabilities 4435 4717 TOTAL EQUITY AND LIABILITIES (1+2+3) 15515 14990 *Represents value less than Rs. 0.50 crore.
Page 19
E3 -torrent- P H RRmA 5 Consolidated Statement of Cash Flows (Rs. in crores) Unaudited Unaudited Particulars Half Year Half Year ended ended 30-Sep-2025 30-Sep-2024 A CASH FLOWS FROM OPERATING ACTIVITIES PROFIT BEFORE TAX 1529 1317 Adjustments for: Depreciation and amortisation expense 405 395 Allowance for expected credit loss (net) 2 1 Unrealised foreign exchange gain (net) (SO) (25) Loss on disposal of property, plant & equipment and other intangible 1 4 assets (net) Gain on sale of current investments (net) (9) (8) Finance costs 104 139 .Interest income (15) (11) 1967 1812 Movement in working capital : Trade receivables (284) 81 Loans and other assets (136) (113) Inventories 75 8 Trade payables {147) 95 Liabilities and provisions (25) 75 CASH GENERATED FROM OPERATIONS 1450 1958 Income taxes paid (net of refunds) (412) (275) NET CASH FROM OPERATING ACTIVITIES 1038 1683 B CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property, plant & equipment and other intangible assets (196) (226) (including payment towards capital work-in-progress, intangible assets under development and capita l advances) Proceeds from disposal of property, plant & equipment and other 2 1 intangib le assets (Including advance received against non current asset held for sale) Payment for non-current investments - {10) Proceeds from redemption of mutual funds (net) 32 64 (Investment in)/Maturity of fixed deposits (net)* {67) 0 Interest received 15 12 NET CASH USED IN INVESTING ACTIVITIES (214) (159) *Represents value less than Rs. 0.50 crore.
Page 20
~ -torrent- ~ PHRR m A (Rs. in crores) Unaudited Unaudited Half Year Half Year Particulars ended ended 30-Sep-2025 30-Sep-2024 C CASH FLOWS FROM FINANCING ACTIVITIES Repayment of long-term borrowings (306) (188) Repayment of short term borrowings (net) (153) (704) Repayment of lease liabilities (23) (11) Dividend paid (203) (203) Interest and other borrowing cost paid (141) (109) NET CASH USED IN FINANCING ACTIVITIES (826) (1215) NET (DECREASE)/ INCREASE IN CASH AND CASH EQUIVALENTS (A+ B + C) (2) 309 Effect of exchange rate changes on foreign currency cash and cash 50 2 equivalents CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD 573 835 CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD 621 1146 6 On June 29, 2025, the Parent Company has entered into definitive agreement with Tau Investment Holdings Pte. Ltd to acquire controlling stake in J.B. Chemicals & Pharmaceuticals Limited (JB Pharma) subject to receipt of applicable statutory and regulatory approva ls. The proposed transaction will be executed in two phases: a) Acquisition of 46.39% equity stake (on fu lly diluted basis) at a cash consideration of Rs. 1600 per equity share aggregating to a total consideration of approximately Rs. 11917 crores and con.duct mandatory open offer at a price of Rs. 1639.18 per equity share in accordance with Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended ("SAST Regulations"). In addition, the Parent Company has entered into definitive agreement with certain employees of JB Pharma, pursuant to which 2.41% equity stake (on fully diluted basis) may be acquired at a price of Rs. 1600 per equity share. b) Merger of JB Pharma with the Parent Company as a going concern through a scheme of arrangement. Upon receipt of requisite approvals, the Parent Company will issue 51 fully paid-up equity shares of the Parent Company having face value of Rs. 5 each for every 100 fully paid-up equity shares of Rs. 1 each held in JB Pharma. The aforesaid transaction has no impact on the results for the quarter and half year ended September 30, 2025. The Parent Company has received approval from Competition Commission of South Africa and Competition Commission of India (CCI) on September 22, 2025 and October 21, 2025 respectively. The CCI approval is subject to the parties comp lying with voluntary modifications to be outlined in CCl's final order . Further the Parent Company has received SEBI Observation on Draft Letter of Offer on October 30, 2025. 7 (i)Exceptional items for the quarter and half year ended September 30, 2025, pertain to regulatory and statutory fees related to the proposed transaction as detailed in Note 6 above. (ii)Exceptional item for the year ended March 31, 2025, relates to a demand raised by the National Pharmaceutical Pricing Authority (NPPA) in 2017 concerning alleged overcharging, which was under judicial consideration before the Hon'ble Gujarat High Court. During the previous year, the Parent Company submitted detailed representations, which were favourably considered by the NPPA. As a result, .the Parent Company's legal exposure was substantially reduced. Following the issuance of a revised demand Parent Company opted to settle the litigation and bring the matter to a definitive close.
Page 21
itlOll-to rre nt- ~ PHRRmR 8 In the previous year, the Parent Company assessed that it would transition to the new tax regime under Section 115BAA starting FY 2025-26. Consequently, deferred tax balances expected to reverse in or after FY 2025-26 were remeasured, resulting in a net reversal of deferred tax liabilities of Rs. 151 crores for the year ended March 31, 2025. 9 Other income mainly includes interest income, net gain on sale of investments, net foreign exchange gain/(loss) and net gain/(loss) on disposal of property, plant & equipment and other intangible assets. 10 Refer Annexure I for disclosure required pursuant to Regulation 52(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). Place: Ahmedabad, Gujarat Date: November 7, 2025 For TORRENT PHARMACEUTICALS LIMITED f.EHTA Managing Director DIN : 08174906
Page 22
~-torr ent- Q;itlll PHARmA ANNEXURE I: (Rs. In crores except as stated other wise) Additional Disclosure as per regulation 52(4) of Securitie s and Exchange Board of India (Listing Obligation s and Disclosure Requirement s) Regulations, 2015 Particul ars Regulation Paid up debt capital Net worth Debentu re redempt ion reserve Debt equity ratio (in times) Debt service coverage ratio (in times) Interest service coverage ratio (in times) Current ratio (in times) long term debt to working capital (in times) Bad debts to Account receivables ratio (in times) Current liability ratio (in tim es) Total debts to total assets (in times) Debtors turno ver (in times) (Annualised) Inventory turnover (in times) (Annualised) Operating margin (in %) Net profit margin (in%) Ratios have been computed as follows :- (a) Debt equity ratio : Total debt/ Net worth Total debt: Non-current borrow ings+ current borrowings Net worth: Equity share capital + Other equity No. 52(4)(f) 52(4)(e) 52(4)(a) 52(4)(b) 52(4)(c) 52(4)(i) 52(4)(j) 52(4)(k) 52(4)(1) 52(4)(m) 52(4)(n) 52(4)(0) 52(4)(p) 52(4)(q) Quarter ended 30-Sep-2025 30-Jun-2025 30-Sep-2024 643 643 786 8449 8137 7504 36 36 71 0.31 0.33 0.41 2.98 5.10 4.89 17.15 14.20 12.03 1.40 1.35 1.21 0.68 0.83 1.22 0.01 0.01 0.01 0.63 0.62 0.64 0.17 0.18 0.20 6.43 6.73 6.31 5.24 4.97 5.00 31.7% 31.1% 31.7% 17.9% 17.2% 15.7% Half Year ended 30-Sep-2025 30-Sep-2024 643 786 8449 7504 36 71 0.31 0.41 3.73 4.64 15.55 11.31 1.40 1.21 0.68 1.22 0.01 0.01 0.63 0.64 0.17 0.20 6.29 6.23 5.09 4.96 31.4% 32.0% 17.6% 15.8% Year ended 31-Mar-2025 643 7591 36 0.40 3.87 12.43 1.19 1.19 0.01 0.64 0.20 6.10 4.7D 32.3% 16.6% (b) Debt service coverage ratio : (Profit after tax+ Deferred tax+ Depreciation and amortisation + Interest on debt and lease + Exceptional item s) / (Interest on debt and lease + Principal repayments of long term debt including lease payment) (c) Interest service coverage ratio: (Profit after tax+ Deferred tax+ Depreciation and amortisation + Interest on debt and lease+ Exceptional items)/ Interest on debt and lease (d) Current Ratio: Total current assets/ Total current liabili ties (e) lon g term debt to working capital : Non-current borrowings (including current maturiti es of long-term borrowings)/ Net working capital Net Working capital : Total current assets - Current liabilities Current liabilities: Total current liabiliti es - current maturities of long-term borrowing s (f) Bad debts to Account receivables ratio : Allowances for expected credit loss/ Gross trade receivables (g) Current liability ratio : Total current liabilities/ Total liabilitie s (h) (i) (j) Total debts to total assets: Total borrowing/ Total assets Total borrowing : Non-current borrowings + current borrowings Debtors turn over : Net sales/ Average trade receivables Inventory turn over : Net sales/ Average Inventories (k) Operating margin%: Revenue from operations - (cost of goods sold+ employee benefits+ other expenses)+ (other income - Interest income· dividend income)/ Revenue from operations (I) Net profit margin % : Profit after tax/ Revenue from operations
Page 23
Torrent Pharma announces Q2 FY26 results Strong branded business performance drives 30% PAT growth Ahmedabad, 7 th November 2025: Torrent Pharmaceuticals Limited (‘’Company”) today announced its financial results for the second quarter of FY 26. Revenue & profitability: Revenue at Rs. 3,302 crores, up by 14% YoY Op. EBITDA* at Rs.1,083 crores, up by 15% YoY Op. EBITDA margin* at 32.8%; Gross Margin: 76% Net Profit after tax at Rs. 591 crores, up by 30% YoY Performance summary: Results Q2 FY26 Q2 FY25 YoY % H1 FY26 H1 FY25 YoY % Rs cr % Rs cr % Rs cr % Rs cr % Revenues 3,302 2,889 14% 6,480 5,748 13% Gross profit 2,502 76% 2,211 77% 13% 4,906 76% 4,376 76% 12% Op EBITDA* 1,083 33% 939 33% 15% 2,115 33% 1,843 32% 15% Exceptional item** (13) 0% 0% - (13) 0% 0% - PAT 591 18% 453 16% 30% 1,139 18% 910 16% 25% R&D spend 156 5% 145 5% 8% 313 5% 280 5% 12% *Before exceptional items ** Exceptional item comprises regulatory and statutory filing fees paid to acquire controlling stake in J.B. Chemicals & Pharmaceuticals Ltd. MEDIA RELEASE ~ -torrent- W PHRRmR In case of any enquiry / clarification , please contact Mr. Jayesh Desai on +91 9824501396 TORRENT PHARMACEUT ICALS LIMITED CIN l24230GJ1972PLC002126 Reg.Office • Torrent House. Off Ashram Road, Ahmedabad • 380 009, India. Phone: +91 79 26599000, Fax · +91 79 26582100, www.torrentpharma.com
Page 24
India: India revenues at Rs 1,820 crores were up by 12% led by outperformance in focus therapies. As per AIOCD secondary market data, IPM growth for the quarter was 8%. Torrent’s chronic business grew at 13% vs IPM growth of 11% On a MAT basis, Torrent has outperformed the market across focused therapies aided by strong new launch performance. Torrent has 21 brands in the Top 500 brands in IPM, with 15 brands having more than Rs.100 crores sales. For H1 FY26, revenues were Rs 3,631 crores, up by 11%. Brazil: Brazil revenues at Rs 318 crores, were up by 21%. Constant currency revenues at R$ 196 million, were up by 13%. As per IQVIA, Torrent grew at 15% vs market growth of 7%. Growth was aided by the performance of top brands & recent launches. Torrent has 65 products under ANVISA review. For H1 FY26, revenues were Rs 536 crores, up by 17% (Constant currency revenue: R$ 340 million, up by 14%). United States: US business revenues at Rs 337 crores, were up by 26%. Constant currency revenues at $39 million, were up by 21% compared to the same period in the previous year. Recent launches have achieved target market shares. For H1 FY26, revenues were Rs 646 crores, up by 23% (Constant currency revenue: $75 million up by 18%). Germany: Germany revenues at Rs 303 crores, were up by 5%. Constant currency revenues at EUR 30 million, were down by 5%. Growth was impacted due to supply disruption at a third party supplier. For H1 FY26, revenues were Rs 612 crores, up by 7% (Constant currency revenue: Euro 62 million, down by 2%). MEDIA RELEASE ~ -torrent- W PHRRmR In case of any enquiry / clarification , please contact Mr. Jayesh Desai on +91 9824501396 TORRENT PHARMACEUT ICALS LIMITED CIN l24230GJ1972PLC002126 Reg.Office • Torrent House. Off Ashram Road, Ahmedabad • 380 009, India. Phone: +91 79 26599000, Fax · +91 79 26582100, www.torrentpharma.com
Page 25
About Torrent Pharmaceuticals Ltd: Torrent Pharma, with annual revenues of more than Rs 11,500 crores, is the flagship Company of the Torrent Group, with group revenues of ~Rs 45,000 crores. It is ranked 7 th in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS) and Cosmo-Dermatology. It is a specialty-focused company with ~76% of its revenues in India from chronic & sub-chronic therapies. It has presence in 50+ countries and is ranked No. 1 amongst the Indian pharma Companies in Brazil and Germany. Torrent has 8 manufacturing facilities, of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing approximately 750+ scientists. MEDIA RELEASE ~ ;orrent- ~ PHRRffiR In case of any enquiry/ clarification, please contact Mr. Jayesh Desai on +91 9824501396 TORRENT PHARMACEUTICALS LIMITED CIN L24230GJ1972PLC002126 Reg.Office Torrent House, Off Ashram Road, Ahmedabad - 380 009, India. Phone: +91 79 26599000, Fax. +91 79 26582100, www torrentpharma.com